#### Open Access Full Text Article

#### REVIEW

# Perineural versus intravenous dexamethasone as an adjuvant in regional anesthesia: a systematic review and meta-analysis

Wen-Ling Zhao<sup>1</sup> Xiao-Feng Ou<sup>1</sup> Jin Liu<sup>1,2</sup> Wen-Sheng Zhang<sup>1,2</sup>

<sup>1</sup>Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Centre, <sup>2</sup>Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China

Correspondence: Wen-Sheng Zhang Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China Tel +86 28 8516 4040 Email zhang\_ws@scu.edu.cn



**Background:** Dexamethasone is a common adjuvant for local anesthetics in regional anesthesia, but the optimal route of administration is controversial. Therefore, we did a systematic review and meta-analysis of randomized controlled trials to assess the effect of perineural versus intravenous dexamethasone on local anesthetic regional nerve-blockade outcomes.

Materials and methods: Medline (through PubMed), Embase, Cochrane, Web of Science, and Biosis Previews databases were systematically searched (published from inception of each database to January 1, 2017) to identify randomized controlled trials. The data of the selected trials were statistically analyzed to find any significant differences between the two modalities. The primary outcome was the duration of analgesia. Secondary outcomes included duration of motor block, postoperative nausea and vomiting, and postoperative analgesic dose at 24 hours. We conducted a planned subgroup analysis to compare the effects between adding epinephrine or not. Results: Ten randomized controlled trials met the inclusion criteria of our analysis, with a total of 749 patients. Without the addition of epinephrine, the effects of perineural and intravenous dexamethasone were equivalent concerning the duration of analgesia (mean difference 0.03 hours, 95% CI -0.17 to 0.24). However, with the addition of epinephrine, the analgesic duration of perineural dexamethasone versus intravenous dexamethasone was prolonged (mean difference 3.96 hours, 95% CI 2.66–5.27). Likewise, the impact of epinephrine was the same on the duration of motor block. The two routes of administration did not show any significant differences in the incidence of postoperative nausea and vomiting, nor on postoperative analgesic consumption at 24 hours.

**Conclusion:** Our results show that perineural dexamethasone can prolong the effects of analgesic duration when compared to the intravenous route, only when epinephrine is coadministered. Without epinephrine, the two modalities show equivalent effect as adjuvants on regional anesthesia. **Keywords:** anesthesia adjuvants, dexamethasone, regional anesthesia

# Introduction

Uncontrolled pain after surgery may produce a range of detrimental acute and chronic effects.<sup>1</sup> In some surgical procedures under regional anesthesia, commonly used local anesthetics cannot provide analgesia for a sufficiently prolonged time. Therefore, local anesthetic–opioid combinations or continuous catheterization are chosen to prolong analgesic duration. However, unintentional opioid-associated side effects and several problems associated with carrying a catheter, especially for day-care patients, make these treatment options unsatisfactory. Since 1982, anesthesiologists have been using a variety of adjuvants added to local anesthetics to enhance regional anesthesia.<sup>2</sup> Dexamethasone is one of these additives.<sup>3</sup>

Journal of Pain Research 2017:10 1529-1543

1529

© 2017 Thao et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Greative Commons Attribution — Non Commercial (unported, v3.0) License (http://creative.commons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Dexamethasone has been proved to be an effective adjuvant for extending the duration of sensory and motor block for peripheral nerve block when given perineurally.<sup>4-6</sup> Intravenous injection can also be used for alleviating postoperative pain.<sup>7</sup> However, there are conflicting reports about which of the two routes of administration is the best or if both exert an equivalent effect.<sup>8-12</sup>

To solve this query, a series of randomized controlled trials (RCTs) were conducted to compare the effect of prolongation of analgesia between perineural and intravenously administered dexamethasone. We carried out a systematic review and meta-analysis to assemble all the associated individual clinical trials to assess the two modalities on the main outcomes: prolonging sensory-block duration, decreasing postoperative nausea and vomiting, and sparing analgesic consumption at 24 hours after surgery.

# Materials and methods

This systematic review and the meta-analysis results were reported following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

# Search strategy

Two authors (WLZ and XFO) independently searched the following databases: Medline (through PubMed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Biosis Previews, from inception of each database to January 1, 2017. There were no language restrictions. The full literature-search strategies for PubMed and Embase are presented in Table S1. In brief, we used MeSH terminology for dexamethasone, regional anesthesia, and their synonyms to search the five databases to obtain relevant literature. Then, all the titles and abstracts were screened and full texts of eligible RCTs retrieved. The references of key English reviews and eligible studies were also manually searched.

# Selection criteria

When the titles and abstracts were screened, four selection criteria were applied: 1) population – adult patients (aged  $\leq$ 19 years) under surgery who received regional anesthesia; 2) intervention – dexamethasone given perineurally as an adjuvant to local anesthetics; 3) control – same-dose dexamethasone given intravenously; and 4) design – RCTs. Studies that satisfied these criteria were retrieved for full texts to be assessed. Meeting abstracts were eliminated due to their incomplete information.

#### Data extraction

Two authors (WLZ and XFO) independently extracted the following raw data from the selected studies: main authors, year of publication, country, number of patients, type of nerve block, ultraguided localization technique, type and dose of local anesthetics (including dexamethasone and other adjuvants), and main outcomes. Then, concrete data of the following outcomes were extracted: duration of analgesia or sensory block, duration of motor block, incidence of postoperative nausea and vomiting, and postoperative analgesic use (morphine equivalents) at 24 hours. For the continuous type of data, we emailed the corresponding author to obtain the raw data when the variables in full text were not reported as means and SD. If authors did not respond, we used a method of data conversion. For calculation of given means, 95% CIs, SD ( $(\sqrt{n} \times [upper - lower]/2t)$ , given medians, and interquartile ranges, the method reported by Hozo et al was used.<sup>13</sup> Each of the two aforementioned authors checked these data at least three times. Any disagreements on the results were resolved independently by a third experienced author (JL).

# Assessment for risk of bias in included studies

Risks of included studies were assessed by the Cochrane risk-of-bias tool. We classified risk of bias as low, unclear, or high for each of random-sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (such as missing participant data). To grade the qualities of evidence and the strength of recommendations, we used GradePro version 3.6.1 for our four outcomes.

# Statistical analysis

Continuous variables, analgesic duration, duration of motor block, and postoperative analgesic use at 24 hours were reported as mean differences (MDs) with 95% CIs. We analyzed postoperative nausea and vomiting as the categorical variable and expressed relative risk with 95% CIs. Heterogeneity of the four outcomes was evaluated by using the  $\chi^2$ and  $I^2$  tests. A fixed-effect model was used when  $\chi^2 P$ -value was >0.1 and  $I^2$ <50%. When P<0.1 and F>50%, we chose a random-effect model, and the planned subgroup analysis was performed to compare adding epinephrine or not to the local anesthetic mixture. Potential publication biases were assessed by funnel-plot analysis. All analyses were performed with RevMan (version 5.3; Cochrane Library, Oxford, UK).

#### **Results** Study selection and characteristics

A flowchart of the study-selection procedure is shown in Figure 1. In order to avoid any missing studies, we did not restrict the design of RCTs in searching Web of Science and Biosis Previews or define the route of administration. A total of 2,939 studies were identified during our first search: 638 articles were removed due to duplication, and 2,301 titles and abstracts were eliminated after screening. Finally, ten studies were included in our ultimateanalysis.14-23 One study was eliminated due to its high standard deviation, which was even larger than the mean value, possibly due to the small-study effect.<sup>24,25</sup> The basic information of the ten studies is presented in Table 1. Patients of seven studies received brachial nerve block, one study used a nerve simulator to localize the nerve, and the rest were ultrasound-guided. The remaining studies were on perianal block, sciatic nerve block, and ankle block. Two of the studies were multicenter clinical trials, which were conducted in Canada and Thailand. The dose of dexamethasone ranged from 4 to 10 mg. Three trials added epinephrine with local anesthetics and dexamethasone, and hence they constituted the planned subgroup analysis in this study.

The risks of bias for the ten studies included here were discussed by all the authors; the risks discussed are summarized in Figure S1. One study<sup>16</sup> did not present the process they used to generate random sequences for group allocation. They also unveiled the allocation results to the anesthesiologists who participated in that trial, and did not refer to any blinding of the outcome assessment, as with another one.<sup>14</sup> For one of the ten studies,<sup>22</sup> the methods section did not clearly show the approach used for blinding the participants.

# Duration of analgesia

The duration of sensory block or analgesia was reported by nine trials. One<sup>19</sup> was eliminated due to its definition of median analgesia time, namely time to first analgesic request in >50% of patients, which was far different to other studies' definitions (Table S2). In a random-effect model, a pooled analysis of nine trials showed that the MD between perineural and intravenous dexamethasone was 1.62 hours (95% CI –0.05 to 3.29, P=80%; P=0.06; Figure 2A), which indicated that dexamethasone given perineurally or intravenously had a similar effect on the duration of sensory block or analgesia. Due to the high heterogeneity, we conducted a subgroup analysis comparing the addition or exclusion of epinephrine. When epinephrine was used, perineural dexamethasone prolonged analgesic duration by 3.96 hours (95% CI 2.66–5.27, P<0.00001)




Figure I Flowchart of the search strategy.

Abbreviation: RCTs, randomized controlled trials.

| Study                                | Country          | <b>c</b>     | Nerve block                                 | Ultrasound-<br>guided    | Local anesthetics (n)   | Outcomes  |
|--------------------------------------|------------------|--------------|---|--------------------------|---|---|
| Abdelmonem and<br>Rizk <sup>14</sup> | Egypt            | 56           | Perianal block                              | Ž                        | Bupivacaine 100 mg + perineural dexamethasone<br>8 mg (18), bupivacaine 100 mg + intravenous<br>dexamethasone 8 mg (19), bupivacaine 100 mg +<br>intravenous normal saline (19)   | Onset of sensory blockade, onset of motor blockade,<br>duration of analgesia, VAS at 6 hours after rescue<br>analgesic, postoperative nausea and vomiting   |
| Desmet et al <sup>15</sup>           | Belgium          | <del>1</del> | Interscalene brachial<br>plexus block       | No (nerve<br>stimulator) | Ropivacaine 150 mg + perineural dexamethasone<br>10 mg (49), ropivacaine 150 mg + intravenous<br>dexamethasone 10 mg (49), ropivacaine 150 mg +<br>intravenous normal saline (46)   | Duration of analgesia, pain scores, motor-block scores,<br>analgesic need, sleep disturbance, overall satisfaction,<br>postoperative blood glucose concentrations   |
| Kawanishi et al <sup>ı6</sup>        | Japan            | 34           | Interscalene brachial<br>plexus block       | Yes                      | Ropivacaine 150 mg + perineural dexamethasone 4 mg<br>(12), ropivacaine 150 mg + intravenous dexamethasone<br>4 mg (10), ropivacaine 150 mg (12)  | Duration of anesthesia, NRS the morning after surgery,<br>analgesic need, sleep disturbance, overall-satisfaction score,<br>postonerative nausea and vomiting, incidence of dysmea  |
| Rahangdale et al <sup>17</sup>       | NSA              | 76           | Sciatic nerve block                         | Yes                      | <ul> <li>Bupivacaine 0.5% 0.45 mL/kg, epinephrine 1:300,000</li> <li>+ perineural dexamethasone 8 mg (27); bupivacaine</li> <li>0.5% 0.45 mL/kg, epinephrine 1:300,000 + intravenous</li> <li>dexamethasone 8 mg (23); bupivacaine 0.5% 0.45 mL/kg, epinephrine 1:300,000 + intravenous normal saline (26)</li> </ul> | Quality of recovery (QoR-40), pain (NRS 0-11), time to<br>first toe movement, analgesia duration, postoperative<br>opioid consumption, patient satisfaction, recommend<br>technique to family or relative, postoperative neurologic<br>symptoms                                   |
| Abdallah et al <sup>Is</sup>         | Canada           | 75           | Supraclavicular<br>brachial plexus<br>block | Yes                      | Bupivacaine 150 mg + perineural dexamethasone<br>8 mg (25), bupivacaine 150 mg + intravenous<br>dexamethasone 8 mg (25), bupivacaine 150 mg +<br>intravenous normal saline (25)   | Duration of analgesia, duration of motor function, VAS<br>pain scores, cumulative intraoperative opioid consumption,<br>cumulative postoperative opioid consumption,<br>postoperative nausea and vomiting, patient satisfaction,<br>occurrence of any block-related comblications |
| Rosenfeld et al <sup>22</sup>        | USA              | 120          | Interscalene brachial<br>plexus block       | Yes                      | Ropivacaine 140 mg + perineural dexamethasone 8 mg<br>(42), ropivacaine 140 mg + intravenous dexamethasone<br>8 mg (37), ropivacaine 140 mg + intravenous normal<br>saline (41)   | Block duration, opioid consumption, VAS, administration of "rescue" antiemetic medication, adverse events   |
| Chun et al <sup>19</sup>             | South Korea      | 66           | Interscalene brachial<br>plexus block       | Yes                      | Ropivacaine 60 mg + perineural dexamethasone 5 mg<br>(50), ropivacaine 60 mg + intravenous dexamethasone<br>5 mg (49)   | Median analgesia time, patient-satisfaction scores, side<br>effects, neurological symptoms, incidence of motor block,<br>analgesic administration, blood glucose values   |
| Aliste et al <sup>23</sup>           | Canada, Thailand | 131          | Axillary brachial<br>plexus block           | Yes                      | Lidocaine 300 mg, bupivacaine 75 mg, epinephrine 150<br>Lidocaine 300 mg, bupivacaine 8 mg (64), bupivacaine<br>10 mg, bupivacaine 75 mg, epinephrine 150 µg +<br>intravenous dexamethasone 8 mg (67)   | Duration of motor block, duration of sensory block,<br>duration of postoperative analgesia  |
| Dawson et al <sup>20</sup>           | Australia        | 06           | Ankle block                                 | Yes                      | Bupivacaine 150 mg + perineural dexamethasone<br>8 mg (30), bupivacaine 150 mg + intravenous<br>dexamethasone 8 mg (30), bupivacaine 150 mg +<br>intravenous normal saline (30)   | Time to return of some sensation or movement, time<br>to return of neurology, pain scores, total postoperative<br>analgesic use   |
| Leurcharusmee<br>et al <sup>21</sup> | Thailand, Canada | 123          | Infraclavicular<br>brachial plexus<br>block | Yes                      | Lidocaine 350 mg, bupivacaine 87.5 mg, epinephrine<br>175 µg + perineural dexamethasone 5 mg (61);<br>lidocaine 350 mg, bupivacaine 87.5 mg, epinephrine  | Duration of motor block, duration of sensory block,<br>duration of postoperative analgesia  |

| Α   | Per     | rineural |         | Intr                | avenous |       |        | Mean difference     | Mean difference                          |
|---|---------|----------|---------|---------------------|---------|-------|--------|---------------------|--|
| Study or Subgroup   | Mean    | SD       | Total   | Mean                | SD      | Total | Weight | IV, random 95% CI   | IV, random 95% CI                        |
| Abdallah et al <sup>18</sup> 2015   | 25      | 9.57     | 25      | 25                  | 7.27    | 25    | 7.3%   | 0.00 [-4.71, 4.71]  |  |
| Abdelmonem and Rizk <sup>14</sup> 2011  | 4.8     | 0.35     | 18      | 4.77                | 0.28    | 19    | 17.4%  | 0.03 [-0.17, 0.23]  | +  |
| Aliste et al <sup>23</sup> 2017   | 21.1    | 4.6      | 64      | 17.1                | 4.6     | 67    | 15.1%  | 4.00 [2.42, 5.58]   |  |
| Dawson et al <sup>20</sup> 2016   | 24.1    | 7.41     | 30      | 20.9                | 7.04    | 30    | 9.5%   | 3.20 [-0.46, 6.86]  |  |
| Desmet et al <sup>15</sup> 2013   | 23.42   | 8.58     | 49      | 21.25               | 11.61   | 49    | 8.6%   | 2.17 [-1.87, 6.21]  |  |
| Kawanishi et al <sup>16</sup> 2014  | 14.5    | 5.04     | 12      | 15.5                | 2.45    | 10    | 10.5%  | -1.00 [-4.23, 2.23] |  |
| eurcharusmee et al <sup>21</sup> 2016   | 22.1    | 8.5      | 61      | 18.6                | 6.7     | 62    | 11.9%  | 3.50 [0.79, 6.21]   |  |
| Rahangdale et al <sup>17</sup> 2014   | 35.5    | 7.7      | 27      | 30.5                | 8.9     | 23    | 7.4%   | 5.00 [0.35, 9.65]   |  |
| Rosenfeld et al <sup>22</sup> 2016  | 16.9    | 5.2      | 42      | 18.2                | 6.4     | 37    | 12.3%  | -1.30 [-3.89, 1.29] |  |
| otal (95% CI)   |         |          | 328     |                     |         | 322   | 100.0% | 1.62 [-0.05, 3.29]  | ◆  |
| leterogeneity: $\tau^2$ =4.17; $\chi^2$ =39<br>est for overall effect: Z=1.90 ( |         |          | 00001); | / <sup>2</sup> =80% |         |       |        |                     |  |
|   | . 5.00) | ,        |         |                     |         |       |        |                     | Favors [intravenous] Favors [perineural] |

| В  | Per   | ineural          |       | Intr   | avenous | ;     |        | Mean difference     | Mean difference                          |
|--|-------|------------------|-------|--------|---------|-------|--------|---------------------|--|
| Study or Subgroup  | Mean  | SD               | Total | Mean   | SD      | Total | Weight | IV, random 95% CI   | IV, random 95% CI                        |
| Epinephrine  |       |                  |       |        |         |       |        |                     |  |
| Aliste et al <sup>23</sup> 2017  | 21.1  | 4.6              | 64    | 17.1   | 4.6     | 67    | 1.6%   | 4.00 [2.42, 5.58]   |  |
| Leurcharusmee et al <sup>21</sup> 2016   | 22.1  | 8.5              | 61    | 18.6   | 6.7     | 62    | 0.5%   | 3.50 [0.79, 6.21]   |  |
| Rahangdale et al <sup>17</sup> 2014  | 35.5  | 7.7              | 27    | 30.5   | 8.9     | 23    | 0.2%   | 5.00 [0.35, 9.65]   |  |
| Subtotal (95% CI)  |       |                  | 152   |        |         | 152   | 2.4%   | 3.96 [2.66, 5.27]   | •  |
| Heterogeneity: $\chi^2$ =0.31, df=2 (F<br>Test for overall effect: Z=5.94 (F                               |       |                  |       |        |         |       |        |                     |  |
| Not epinephrine  |       |                  |       |        |         |       |        |                     |  |
| Abdallah et al <sup>18</sup> 2015  | 25    | 9.57             | 25    | 25     | 7.27    | 25    | 0.2%   | 0.00 [-4.71, 4.71]  |  |
| Abdelmonem and Rizk <sup>14</sup> 2011   | 4.8   | 0.35             | 18    | 4.77   | 0.28    | 19    | 95.9%  | 0.03 [-0.17, 0.23]  |  |
| Dawson et al <sup>20</sup> 2016  | 24.1  | 7.41             | 30    | 20.9   | 7.04    | 30    | 0.3%   | 3.20 [-0.46, 6.86]  |  |
| Desmet et al <sup>15</sup> 2013  | 23.42 | 8.58             | 49    | 21.25  | 11.61   | 49    | 0.2%   | 2.17 [-1.87, 6.21]  |  |
| Kawanishi et al <sup>16</sup> 2014   | 14.5  | 5.04             | 12    | 15.5   | 2.45    | 10    | 0.4%   | -1.00 [-4.23, 2.23] |  |
| Rosenfeld et al <sup>22</sup> 2016   | 16.9  | 5.2              | 42    | 18.2   | 6.4     | 37    | 0.6%   | -1.30 [-3.89, 1.29] |  |
| Subtotal (95% CI)  |       |                  | 176   |        |         | 170   | 97.6%  | 0.03 [-0.17, 0.24]  | •  |
| Heterogeneity: χ <sup>2</sup> =0.31, <i>df</i> =2 ( <i>F</i><br>Test for overall effect: Z=5.94 ( <i>F</i> |       |                  |       |        |         |       |        |                     |  |
| Total (95% CI)   |       |                  | 328   |        |         | 322   | 100.0% | 0.13 [–0.08, 0.33]  | •  |
| Heterogeneity: $\chi^2$ =39.56, <i>df</i> =8<br>Test for overall effect: Z=1.23 (                          |       | 001); <i>l</i> ² | =80%  |        |         |       |        |                     | -10 -5 0 5 10                            |
| T  | · ,   |                  |       | aa 1 2 |         |       |        |                     | Favors [intravenous] Favors [perineural] |

Test for subgroup differences:  $\chi^2$ =33.90, *df*=1 (*P*<0.00001); *l*<sup>2</sup>=97.0%

Figure 2 Forest plots showing the duration of analgesia.

Notes: Analysis of all data in the associated studies (A); subgroup analysis by differentiating addition or not of epinephrine (B).

in comparison to the intravenous dexamethasone group, with no heterogeneity ( $I^2=0$ ). In the absence of epinephrine, both groups had equal analgesic duration (MD 0.03 hours,  $I^2=7\%$ , 95% CI –0.17 to 0.24; P=0.75; Figure 2B). There were no observations of publication biases when constructing the funnel plots (Figure S2).

#### Duration of motor block

Four trials reported on duration of motor block. The effects on prolonging duration of motor block between the two modalities was statistically insignificant (MD 1.67 hours, P=94%, 95% CI –2.88 to 6.22; P=0.47; Figure 3A) as revealed by the random-effect model. However, subgroup analysis showed that in the presence of epinephrine, the perineural dexamethasone group had duration prolonged by 4 hours (95% CI 2.82–5.20, P=3%; P<0.00001; Figure 3B) when compared to the intravenous dexamethasone group.

#### Postoperative nausea and vomiting

Six studies assessed the incidence of postoperative nausea and vomiting. The pooled analysis demonstrated that there was no difference between the perineural and intravenous dexamethasone groups (risk ratio 0.87, 95% CI 0.35–2.11; P=0.75; Figure 4A), without heterogeneity ( $l^2=0$ ) or publication bias (Figure S3).


#### Postoperative analgesic use at 24 hours

Postoperative opioid consumption (morphine equivalents) at 24 hours was evaluated by three trials. In this analysis, analgesic use was the same between the two groups (MD -3.66 mg, *P*=0, 95% CI -8.67 to 1.34; *P*=0.15; Figure 4B).

# Grade quality

GradePro evaluation of the confidence of evidence is shown in Table 2.

|  | Per       | ineura |        | Intra              | avenous | 5     |        | Mean difference      | Mean difference                          |
|--|-----------|--------|--------|--------------------|---------|-------|--------|----------------------|--|
| Study or Subgroup  | Mean      | SD     | Total  | Mean               | SD      | Total | Weight | IV, random 95% CI    | IV, random 95% CI                        |
| Abdallah et al <sup>18</sup> 2015  | 25.5      | 4.6    | 25     | 30.1               | 2.66    | 25    | 25.7%  | -4.60 [-6.68, -2.52] |  |
| Aliste et al <sup>23</sup> 2017  | 17.5      | 4.6    | 64     | 12.8               | 4.5     | 67    | 26.3%  | 4.70 [3.14, 6,26]    |  |
| Leurcharusmee et al <sup>21</sup> 2016                                     | 15.7      | 6.2    | 61     | 12.9               | 5.5     | 62    | 25.7%  | 2.80 [0.73, 4.87]    |  |
| Rahangdale et al <sup>17</sup> 2014  | 29.9      | 7.3    | 27     | 25.9               | 7.2     | 23    | 22.4%  | 4.00 [-0.03, 4.03]   |  |
| Total (95% CI)   |           |        | 177    |                    |         | 177   | 100.0% | 1.67 [-2.88, 6.22]   |  |
| Heterogeneity: $\tau^2$ =19.85; $\chi^2$<br>Test for overall effect: Z=0.7 |           |        | <0.000 | 01); <i>l</i> ²=94 | 1%      |       |        |                      |  |
|  | 2 (7 -0.4 | ,,     |        |                    |         |       |        |                      | Favors [intravenous] Favors [perineural] |



#### Figure 3 Forest plots showing the duration of motor block.

Notes: Analysis of four studies (A) and subgroup analysis by differentiating addition or not of epinephrine (B).

Α

|  | Perineu | ıral  | Intraveno | JS    |        | Risk Ratio          | Mean difference  |
|--|---------|-------|-----------|-------|--------|---------------------|--|
| Study or Subgroup  | Events  | Total | Events    | Total | Weight | M-H, fixed, 95% CI  | IV, random 95% CI  |
| Dawson et al <sup>20</sup> 2016  | 0       | 30    | 0         | 30    |        | Not estimable       |  |
| Kawanishi <sup>16</sup> 2014   | 0       | 12    | 1         | 10    | 16.7%  | 0.28 [0.01, 6.25]   |  |
| Chun et al <sup>19</sup> 2016  | 3       | 50    | 6         | 49    | 62.5%  | 0.49 [0.13, 1.85]   |  |
| Abdallah <sup>18</sup> 2015  | 1       | 25    | 1         | 25    | 10.3%  | 1.00 [0.07, 15.12]  |  |
| Rosenfeld <sup>22</sup> 2016   | 1       | 42    | 0         | 37    | 5.5%   | 2.65 [0.11, 63.16]  |  |
| Abdelmonem and Rizk <sup>14</sup> 2011   | 2       | 18    | 0         | 19    | 5.0%   | 5.26 [0.27, 102.66] |  |
| Total (95% CI)   |         | 177   |           | 170   | 100.0% | 0.87 [0.35, 2.11]   | -  |
| Total events   | 7       |       | 8         |       |        |                     |  |
| Heterogeneity: $\chi^2$ =3.12, <i>df</i> =4 (<br>Test for overall effect: Z=0.32 ( |         | =0%   |           |       |        |                     | 0.002 0.1 1 10 500<br>Favors [perineural] Favors [intravenous] |

|  | Pe   | rineural |       | Inti | avenous |       |        | Mean difference       |                       | Mean diff     | ference                    |    |
|--|------|----------|-------|------|---------|-------|--------|-----------------------|-----------------------|---------------|----------------------------|----|
| Study or Subgroup  | Mean | SD       | Total | Mean | SD      | Total | Weight | IV, fixed 95% CI      |                       | IV, random    | n 95% CI                   |    |
| Abdallah <sup>18</sup> 2015                                  | 13.3 | 29.55    | 25    | 12.5 | 24.47   | 25    | 11.1%  | 0.00 [-14.24, 15.84]  |                       |               |                            |    |
| Rahangdale <sup>17</sup> 2014                                | 30.3 | 25.6     | 27    | 31.3 | 20.2    | 23    | 15.5%  | –1.00 [–13.70, 11.70] |                       |               |                            |    |
| Rosenfeld <sup>22</sup> 2016                                 | 12.2 | 9.3      | 42    | 17.1 | 15.9    | 37    | 73.4%  | -4.90 [-10.74, 0.94]  |                       |               |                            |    |
| Total (95% CI)   |      |          | 94    |      |         | 85    | 100.0% | -3.66 [-8.67, 1.34]   |                       | •             |                            |    |
| Heterogeneity: $\chi^2$ =3.12,<br>Test for overall effect: Z |      |          | 0%    |      |         |       |        | ⊢<br>_5               | 50 –25<br>Favors [per | 0<br>ineural] | 25<br>Favors [intravenous] | 50 |

Figure 4 Forest plots comparing perineural and intravenous groups at 24 hours.

Notes: Incidence of postoperative nausea and vomiting (A); postoperative analgesic consumption (B).

| Outcomes   | Number of I  | Number of participants                              | Ouality assessment                                | nent                                      |   |   |  |  | Ouality of   |
|--|--|---|---|---|---|---|--|--|--|
|  | Perineural   | Perineural Intravenous                              | Study design                                      | Risk of bias                              | Risk of bias Inconsistency                        | Indirectness                                  | Imprecision                                  | <b>Publication bias</b>                                  | evidence (grade)   |
| Duration of analgesia: epinephrine<br>(three studies) <sup>17,18,22</sup>  | 152  | 152   | RCT   | Not serious                               | Not serious                                       | Not serious                                   | Serious <sup>a</sup>                         | Not serious  | ⊕⊕⊕⊝<br>Moderate   |
| Duration of analgesia: not epinephrine (six studies) <sup>14,16,18,19,20,22</sup>  | 176  | 170   | RCT   | Not serious                               | Not serious                                       | Not serious                                   | Serious <sup>b</sup>                         | Not serious  | ⊕⊕⊕⊝<br>Moderate   |
| Duration of motor block: epinephrine (three studies) <sup>17,18,22</sup>   | 152  | 152   | RCT   | Not serious                               | Not serious                                       | Not serious                                   | Serious <sup>a</sup>                         | Not serious  | ⊕⊕⊕⊝<br>Moderate   |
| Postoperative nausea and vomiting (six studies) <sup>14,16,18,19,20,22</sup>   | 177  | 170   | RCT   | Not serious                               | Not serious                                       | Not serious                                   | Serious <sup>b</sup>                         | Not serious  | ⊕⊕⊕⊝<br>Moderate   |
| Postoperative opioid use at 24 hours<br>(three studies) <sup>17,18,22</sup>  | 94   | 85  | RCT   | Not serious                               | Not serious                                       | Not serious                                   | Serious <sup>a,b</sup>                       | Not serious  | ⊕⊕⊕⊝<br>Moderate   |
| Notes: "Number of RCTs not sufficient: "results had wide Cls around the estimated effect. High quality: further research very unlikely to change our confidence in the estimate of effect. Moderate quality: further research likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research very likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate. | ults had wide CIs a<br>e estimate of effect<br>tain about the esti | around the estimate<br>t and may change th<br>mate. | d effect. High quality:<br>1e estimate. Low quali | further research v<br>ty: further researc | ery unlikely to change<br>h very likely to have a | e our confidence in tl<br>an important impact | he estimate of effect<br>on our confidence i | : Moderate quality: furthe<br>n the estimate of effect a | er research likely to have<br>nd is likely to change the |

Abbreviation: RCT, randomized controlled trial

#### Discussion

The results of our review and meta-analysis show that the two modalities of perineural and intravenous dexamethasone as local anesthetic additives can produce a similar effect on the duration of analgesia or sensory block. From the subgroup analysis, we found that the high heterogeneity in the data analysis stemmed from adding epinephrine or not, a well-known adjuvant in local anesthetics to prolong block duration.<sup>26,27</sup> With epinephrine, prolongation of duration of analgesia and motor block were observed in the perineural dexamethasone group when compared to the intravenous dexamethasone method. Without epinephrine, both groups showed an equivalent effect on analgesia duration. In addition, the incidence of postoperative nausea and vomiting and postoperative analgesic consumption at 24 hours exhibited no statistical significant differences when comparing the two routes of administration.

Such adjuvants as midazolam,28 ketamine,29 clonidine,30 dexmedetomidine,<sup>31</sup> epinephrine, or dexamethasone are coadministered with local anesthetics in order to enhance the effect of single-shot peripheral nerve block. Although several meta-analyses<sup>4-6</sup> have demonstrated that dexamethasone given perineurally can extend the analgesic duration of common local anesthetics for brachial plexus block, the effectiveness of intravenous dexamethasone has been controversial.<sup>12</sup> Actually, in a meta-analysis of 38 studies, systemic dexamethasone (>0.1 mg·kg<sup>-1</sup>) reduced postoperative pain and analgesic consumption.7 As such, the current paramount issue is to demonstrate that perineural dexamethasone has an extra effect on the duration of analgesia through a direct mechanism on nerve blocking.32 In this meta-analysis, the pooled results from ten RCTs revealed that dexamethasone (4–10 mg) can produce similar duration of sensory or motor block when administered perineurally or intravenously without epinephrine. In other words, the viewpoint that dexamethasone has a direct inhibition of peripheral nerves needs to be considered carefully and examined again. However, limited evidence in our review and meta-analysis elucidates that there may be a synergistic effect between dexamethasone and epinephrine when given locally.

On the one hand, whether or not dexamethasone has a direct effect on nerve conduction has been disputed. In isolated rat sciatic nerves, neither dexamethasone nor buprenorphine can inhibit the compound action potentials from A and C fibers.<sup>33</sup> In vivo, an animal study demonstrated that bupivacaine plus 67  $\mu$ g dexamethasone did not increase block duration more than bupivacaine alone.<sup>34</sup> In contrast, in a mouse sciatic nerve-blockade model, high-dose (0.5 mg·kg<sup>-1</sup>) perineural dexamethasone added to bupivacaine prolonged the duration of sensory and motor block, while low-dose (0.14 mg·kg<sup>-1</sup>) dexame has one did not. However, these results should be considered with skepticism, because of the unblinded procedure in that study.<sup>35</sup> Despite the fact that sciatic nerves are commonly used to evaluate the effect of local anesthetic, we cannot directly extrapolate the results from rodents to humans. In addition, the period of block conduction can differ due to the neurobiology of acute postoperative pain in clinical patients. Acute postoperative pain includes not the conduction of nociception, but direct nerve damage and inflammatory mediator release, which activate peripheral nociceptors to deliver information to the central nervous system.1 Dexamethasone, a long-effective glucocorticoid, has the appropriate anti-inflammatory property by increasing the production of anti-inflammatory substances and decreasing the release of inflammatory mediators.<sup>36</sup> This characteristic may be responsible for its systematic mechanism in prolonging block duration. Overall, further studies are needed to find and prove the precise indirect mechanism of dexamethasone and also its interaction with epinephrine perineurally.

On the other hand, dexamethasone is prescribed "offlabel" for perineural administration. Neurotoxicity is a serious problem for local anesthetics and additives that we have to consider. Dexamethasone 133  $\mu g \cdot m L^{-1}$  combined with ropivacaine increased neurotoxicity for isolated sensory neurons. As such, the author advised that much attention be paid to the time- and concentration-dependent toxicity when dexamethasone is combined with ropivacaine.37 In agreement with previous results, 38,39 in a preliminary animal experiment, we found that solutions of commonly used local anesthetics (bupivacaine, ropivacaine) in combination with nonparticulate dexamethasone sodium phosphate could crystallize, even in physiological pH (unpublished data). Therefore, the patient's safety might be compromised when crystalliferous solution is unintentionally injected into the subarachnoid space or into the blood vessels.

Considering potential neurotoxicity or hazards from crystallization, the unknown mechanism of action, and the fact that both methods have a similar effect on block duration, controlling nausea and vomiting, and sparing opioid consumption, we conclude that intravenous dexamethasone is preferable to perineural dexamethasone, as it carries fewer risks to the patient. Moreover, a recent published meta-analysis<sup>40</sup> proved that a combination of intravenous dexamethasone with other antiemetics showed more efficacy than a single antiemetic in preventing nausea and vomiting after laparoscopic cholecystectomy.

There are some limitations of this analysis. Firstly, postoperative blood glucose levels and long-term neurological sequelae were not analyzed. Only two of the ten trials<sup>15,19</sup> chosen here reported blood glucose concentrations after surgery. In these two studies, data demonstrated that there were no significant differences in blood glucose levels between the two routes of administration. Also, no serious relevant neurologic symptoms were found in these clinical trials. Secondly, although heterogeneity was low or inexistent among the four outcomes, there was a risk of bias in some of the studies. Thirdly, this review did not evaluate the interaction between the dosage of dexamethasone and block duration. However, Albrecht et al<sup>41</sup> elucidated that no inconclusive evidence was found between different concentrations of dexamethasone (4–10 mg) and analgesic duration by subgroup analysis.

Knowledge on many aspects of the two modalities is not clear, and further clinical studies are required to explore and determine their mechanism of action. A large-scale, multicenter, prospective, double-blinded RCT is needed to be performed to prove which is the most effective adjuvant, the best method of delivery (local anesthetic, perineural, or intravenous dexamethasone), and whether dexamethasone has a synergistic or additive effect with epinephrine when administered locally. If the most efficient route of administration proves to be additive, then the optimal dose of dexamethasone has to be determined. Finally, prospective studies should investigate the safety of dexamethasone at higher doses (>133  $\mu$ g·mL<sup>-1</sup>), when administered perineurally with local anesthetics.

#### Conclusion

Our systematic review and meta-analysis suggests that local epinephrine and dexamethasone have a synergistic effect. However, without epinephrine, intravenous dexamethasone and perineural dexamethasone share similar effects on block duration, postoperative nausea and vomiting, and postoperative analgesic consumption at 24 hours. At present, and considering the potential risk of the off-label use of dexamethasone perineurally and its as yet unknown mechanism of action, the route of intravenous administration is thus preferable. Further animal and human studies are needed to explore the definite relationship and the potential synergistic mechanism between local dexamethasone and epinephrine and to select the most effective route of administration required to guide clinical practice.

# Acknowledgment

The authors show much gratitude to Robert McCarthy for supplying the raw data presented in their studies.

# Disclosure

The authors report no conflicts of interest in this work.

#### References

- 1. Miller RD. *Miller's Anesthesia*. 7th ed. Philadelphia: Churchill Livingstone; 2009.
- Candido KD, Knezevic NN. All adjuvants to local anesthetics were not created equal: animal data evaluating neurotoxicity, thermal hyperalgesia, and relevance to human application. *Reg Anesth Pain Med*. 2011;36(3):211–212.
- Kirksey MA, Haskins SC, Cheng J, Liu SS. Local anesthetic peripheral nerve block adjuvants for prolongation of analgesia: a systematic qualitative review. *PloS One*. 2015;10(9):e0137312.
- Arulkumar S, Elnagar I, Hamilton C, Fox C. Dexamethasone as an adjunct for brachial plexus blockade: meta-analysis. 2014. Available from: http://www.lsuhscshreveport.edu/Assets/uploads/LSUHealth-Shreveport/Documents/Anesthesiology/Posters/DexamethasoneRegionalAnesthesiaIARS2014.pdf. Accessed June 13, 2017.
- Huynh TM, Marret E, Bonnet F. Combination of dexamethasone and local anaesthetic solution in peripheral nerve blocks: A meta-analysis of randomised controlled trials. *Eur J Anaesthesiol*. 2015;32(11):751–758.
- Choi S, Rodseth R, McCartney CJ. Effects of dexamethasone as a local anaesthetic adjuvant for brachial plexus block: a systematic review and meta-analysis of randomized trials. *Br JAnaesth*. 2014;112(3):427–439.
- De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a metaanalysis of randomized controlled trials. *Anesthesiology*. 2011;115(3): 575–588.
- Lee S, Choi S. Intravenous and perineural dexamethasone in peripheral nerve block: are they truly equivalent? *Anesth Analg.* 2015;121(1):251.
- Sondekoppam RV, Uppal V, Ganapathy S. Intravenous or perineural dexamethasone for interscalene brachial plexus block: the equivalence not yet proven. *Br J Anaesth*. 2014;112(1):175–176.
- Tighe SQ. Perineural or intravenous dexamethasone: do we still need catheters? *Anaesthesia*. 2016;71(8):983–984.
- Bolin ED, Wilson S. Perineural versus systemic dexamethasone: questions remain unanswered. *Reg Anesth Pain Med.* 2015;40(4):393–394.
- Albrecht E, Kern C, Kirkham KR. Perineural vs intravenous administration of dexamethasone: more data are available. *Br J Anaesth*. 2015;114(1):160.
- 13. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005;5:13.
- Abdelmonem A, Rizk SN. Comparative study between intravenous and local dexamethasone as adjuvant to bupivacaine in perianal block. *Egypt J Anaesth.* 2011;27(3):163–168.
- Desmet M, Braems H, Reynvoet M, et al. I.V. and perineural dexamethasone are equivalent in increasing the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder surgery: a prospective, randomized, placebo-controlled study. *Br J Anaesth*. 2013;111(3): 445–452.
- Kawanishi R, Yamamoto K, Tobetto Y, et al. Perineural but not systemic low-dose dexamethasone prolongs the duration of interscalene block with ropivacaine: a prospective randomized trial. *Local Reg Anesth*. 2014;7:5–9.
- Rahangdale R, Kendall MC, McCarthy RJ, et al. The effects of perineural versus intravenous dexamethasone on sciatic nerve blockade outcomes: a randomized, double-blind, placebo-controlled study. *Anesth Analg.* 2014;118(5):1113–1119.

- Abdallah FW, Johnson J, Chan V, et al. Intravenous dexamethasone and perineural dexamethasone similarly prolong the duration of analgesia after supraclavicular brachial plexus block: a randomized, triple-arm, double-blind, placebo-controlled trial. *Reg Anesth Pain Med*. 2015;40(2):125–132.
- Chun EH, Kim YJ, Woo JH. Which is your choice for prolonging the analgesic duration of single-shot interscalene brachial blocks for arthroscopic shoulder surgery? Intravenous dexamethasone 5 mg vs. perineural dexamethasone 5 mg randomized, controlled, clinical trial. *Medicine (Baltimore)*. 2016;95(23):e3828.
- Dawson RL, McLeod DH, Koerber JP, Plummer JL, Dracopoulos GC. A randomised controlled trial of perineural vs intravenous dexamethasone for foot surgery. *Anaesthesia*. 2016;71(3):285–290.
- Leurcharusmee P, Aliste J, Van Zundert TC, et al. A multicenter randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided infraclavicular block. *Reg Anesth Pain Med*. 2016;41(3):328–333.
- 22. Rosenfeld DM, Ivancic MG, Hattrup SJ, et al. Perineural versus intravenous dexamethasone as adjuncts to local anaesthetic brachial plexus block for shoulder surgery. *Anaesthesia*. 2016;71(4):380–388.
- Aliste J, Leurcharusmee P, Engsusophon P, et al. A randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided axillary block. *Can J Anaesth.* 2017;64(1):29–36.
- Morales-Muñoz C, Sánchez-Ramos JL, Diaz-Lara MD, González-González J, Gallego-Alonso I, Hernández-del-Castillo MS. Analgesic effect of a single-dose of perineural dexamethasone on ultrasoundguided femoral nerve block after total knee replacement. *Rev Esp Anestesiol Reanim*. 2017;64(1):19–26.
- Rücker G, Carpenter JR, Schwarzer G. Detecting and adjusting for small-study effects in meta-analysis. *Biom J.* 2011;53(2):351–368.
- 26. Niemi G, Breivik H. Adrenaline markedly improves thoracic epidural analgesia produced by a low-dose infusion of bupivacaine, fentanyl and adrenaline after major surgery: a randomised, double-blind, crossover study with and without adrenaline. *Acta Anaesthesiol Scand*. 1998;42(8):897–909.
- Sakaguchi Y, Sakura S, Shinzawa M, Saito Y. Does adrenaline improve epidural bupivacaine and fentanyl analgesia after abdominal surgery? *Anaesth Intensive Care*. 2000;28(5):522–526.
- Boussofara M, Carles M, Raucoules-Aime M, Sellam MR, Horn JL. Effects of intrathecal midazolam on postoperative analgesia when added to a bupivacaine-clonidine mixture. *Reg Anesth Pain Med.* 2006;31(6):501–505.
- Kazemeini A, Rahimi M, Fazeli MS, et al. The effect of local injections of bupivacaine plus ketamine, bupivacaine alone, and placebo on reducing postoperative anal fistula pain: a randomized clinical trial. *ScientificWorldJournal*. 2014;2014:424152.
- Trifa M, Engelhardt T, Khalifa SB. The addition of clonidine to bupivacaine in saphenous/sciatic nerve blocks in children. *Paediatr Anaesth*. 2016;26(3):321–322.
- Xiang Q, Huang DY, Zhao YL, et al. Caudal dexmedetomidine combined with bupivacaine inhibit the response to hernial sac traction in children undergoing inguinal hernia repair. *Br J Anaesth*. 2013;110(3):420–424.
- 32. Martinez V, Fletcher D. Dexamethasone and peripheral nerve blocks: on the nerve or intravenous? *Br J Anaesth*. 2014;113(3):338–340.
- Yilmaz-Rastoder E, Gold MS, Hough KA, Gebhart GF, Williams BA. Effect of adjuvant drugs on the action of local anesthetics in isolated rat sciatic nerves. *Reg Anesth Pain Med.* 2012;37(4):403–409.
- Buvanendran A, Kroin JS, Li J, Moric M, Tuman KJ. Relative contribution of adjuvants to local anesthetic for prolonging the duration of peripheral nerve blocks in rats. *Reg Anesth Pain Med.* 2016;41(5): 589–592.
- 35. An K, Elkassabany NM, Liu J. Dexamethasone as adjuvant to bupivacaine prolongs the duration of thermal antinociception and prevents bupivacaine-induced rebound hyperalgesia via regional mechanism in a mouse sciatic nerve block model. *PloS One*. 2015;10(4):e0123459.
- Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci (Lond)*. 1998;94(6):557–572.

- Williams BA, Hough KA, Tsui BY, Ibinson JW, Gold MS, Gebhart GF. Neurotoxicity of adjuvants used in perineural anesthesia and analgesia in comparison with ropivacaine. *Reg Anesth Pain Med*. 2011;36(3):225–230.
- Watkins TW, Dupre S, Coucher JR. Ropivacaine and dexamethasone: a potentially dangerous combination for therapeutic pain injections. *J Med Imaging Radiat Oncol.* 2015;59(5):571–577.
- Hwang H, Park J, Lee WK, et al. Crystallization of local anesthetics when mixed with corticosteroid solutions. *Ann Rehabil Med.* 2016;40(1): 21–27.
- 40. Awad K, Ahmed H, Abushouk AI, et al. Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: an updated systematic review and meta-analysis. *Int J Surg.* 2016; 36(Pt A):152–163.
- 41. Albrecht E, Kern C, Kirkham KR. A systematic review and metaanalysis of perineural dexamethasone for peripheral nerve blocks. *Anaesthesia*. 2015;70(1):71–83.

# Supplementary materials

#### Table SI Search strategy

| #  | PubMed   |
|----|--|
| I  | Search ((((((((((((((((((((((((((((((((((((  |
| 2  | Search ((((Anesthesia, Conduction[MeSH Terms]) OR Anesthesia, Conduction[Text Word]) OR Conduction Anesthesia[Text Word]) OR Anesthesia[Regional[Text Word]) OR Regional Anesthesia[Text Word]   |
| 3  | Search ((((((((((((((((((((((((((((((((((((  |
| 4  | Search (((((Anesthesia, Caudal[MeSH Terms]) OR Anesthesia, Caudal[Text Word]) OR Caudal Anesthesia[Text Word]) OR Anesthesia,<br>Sacral Epidural[Text Word]) OR Epidural Anesthesia, Sacral[Text Word]) OR Sacral Epidural Anesthesia[Text Word]   |
| 5  | Search ((((((Anesthesia, Local[MeSH Terms]) OR Anesthesia, Local[Text Word]) OR Local Anesthesia[Text Word]) OR Anesthesia,<br>Infiltration[Text Word]) OR Infiltration Anesthesia[Text Word]) OR Neural Therapy of Huneke[Text Word]) OR Huneke Neural<br>Therapy[Text Word]  |
| 6  | Search ((((Anesthesia, Spinal[MeSH Terms]) OR Anesthesia, Spinal[Text Word]) OR Anesthesias, Spinal[Text Word]) OR Spinal<br>Anesthesia[Text Word]) OR Spinal Anesthesias[Text Word]   |
| 7  | Search ((((((((((((((((((((((((((((((((((((  |
| 8  | Search ((((((Anesthetics, Local[MeSH Terms]) OR Anesthetics, Local[Text Word]) OR Local Anesthetics[Text Word]) OR Conduction-<br>Blocking Anesthetics[Text Word]) OR Conduction Blocking Anesthetics[Text Word]) OR Anesthetics, Conduction-Blocking[Text Word])<br>OR Anesthetics, Conduction Blocking[Text Word]) OR Anesthetics, Topical[Text Word]  |
| 9  | Search (amydricaine[Text Word] OR amylocaine[Text Word] OR articaine[Text Word] OR aslavital[Text Word] OR benzocaine[Text Word] OR bucciaine[Text Word] OR butciaine[Text Word] OR butciaine[Text Word] OR bucciaine[Text Word] OR cartisocaine[Text Word] OR centbucridine[Text Word] OR cetacaine[Text Word] OR chloroprocaine[Text Word] OR carticaine[Text Word] OR centbucridine[Text Word] OR cetacaine[Text Word] OR chloroprocaine[Text Word] OR conclusine[Text Word] OR conclusine[Text Word] OR dibucaine[Text Word] OR diperodon[Text Word] OR cyclomethycaine[Text Word] OR dibucaine[Text Word] OR embalter Word] OR ethyl chloride[Text Word] OR etidocaine[Text Word] OR eugenol[Text Word] OR eugenol[Text Word] OR fluress[Text Word] OF fomocaine[Text Word] OR guafecainol[Text Word] OR heptacaine[Text Word] OR heptacaine[Text Word] OR kextorine[Text Word] OR hepsicaine[Text Word] OR instillagel[Text Word] OR ipravacaine[Text Word] OR pentacaine[Text Word] OR kecocaine[Text Word] OR levobupivacaine[Text Word] OR pentacaine[Text Word] OR pentacaine[Text Word] OR pentacaine[Text Word] OR procaine[Text Word] OR procaine[Text Word] OR pentacaine[Text Word] OR procaine[Text Word] OR procai |
| 10 | OR xyloproct[Text Word] OR zolamine[Text Word])<br>Search ((clinical[tiab] AND trial[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR "random<br>allocation"[mesh] OR "therapeutic use"[sh])   |
|    | 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9   |

- 11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
- 12 I and II and I0

| #        | Embase   |
|----------|--|
| I        | exp dexamethasone  |
| 2        | (dexamethasone or Methylfluorprednisolone or Hexadecadrol or Decameth or Foy Brand of Dexamethasone or Decaspray or Merck Bran             |
|          | of Dexamethasone or Dexasone or ICN Brand of Dexamethasone or Dexpak or ECR Brand of Dexamethasone or Maxidex or Alcon Brar                |
|          | of Dexamethasone or Millicorten or Oradexon or Decaject or Merz Brand I of Dexamethasone or Decaject-L A or Decaject L A or Merz           |
|          | Brand 2 of Dexamethasone or Hexadrol).tw.  |
| 3        | exp regional anesthesia  |
| 1        | (Anesthesia, Conduction or Conduction Anesthesia or Anesthesia, Regional or Regional Anesthesia).tw.                                       |
| 5        | exp epidural anesthesia  |
| <b>b</b> | (Anesthesia, Epidural or Anesthesia, Peridural or Anesthesias, Peridural or Peridural Anesthesia or Peridural Anesthesias or Anesthesia,   |
|          | Extradural or Anesthesias, Extradural or Extradural Anesthesia or Extradural Anesthesias or Epidural Anesthesia or Anesthesias, Epidural o |
|          | Epidural Anesthesias).tw.  |
| 7        | exp caudal anesthesia  |
| 3        | (Anesthesia, Caudal or Caudal Anesthesia or Anesthesia, Sacral Epidural or Epidural Anesthesia, Sacral or Sacral Epidural Anesthesia).tw.  |
| 9        | exp local anesthesia   |
| 10       | (Anesthesia, Local or Local Anesthesia or Anesthesia, Infiltration or Infiltration Anesthesia or Neural Therapy of Huneke or Huneke Neura  |
|          | Therapy).tw.   |
| I        | exp spinal anesthesia  |
| 2        | (Anesthesia, Spinal or Anesthesias, Spinal or Spinal Anesthesia or Spinal Anesthesias).tw.   |
| 3        | exp nerve block  |
| 4        | (Nerve Block or Block, Nerve or Blocks, Nerve or Nerve Blocks or Nerve Blockade or Blockade, Nerve or Blockades, Nerve or Nerve            |
|          | Blockades or Chemical Neurolysis or Chemical Neurolyses or Neurolyses, Chemical or Neurolysis, Chemical or Chemodenervation or             |
|          | Chemodenervations).tw.   |
| 5        | exp local anesthetic agent   |
| 6        | (Anesthetics, Local or Local Anesthetics or Conduction-Blocking Anesthetics or Conduction Blocking Anesthetics or Anesthetics,             |
|          | Conduction-Blocking or Anesthetics, Conduction Blocking or Anesthetics, Topical).tw.   |
| 7        | (amydricaine or amylocaine or articaine or aslavital or benzocaine or benzofurocaine or bucricaine or bumecaine or bupivacaine or          |
|          | butacaine or butanilicaine or butethamine or butoxycaine or butylcaine or carbisocaine or carticaine or centbucridine or cetacaine or      |
|          | chloroprocaine or cinchocaine or cocaine or cyclomethycaine or dibucaine or dimethocaine or diperodon or diphenhydramine or dyclonin       |
|          | or emLa or ethyl chloride or etidocaine or eugenol or euprocin or fluress or fomocaine or guafecainol or heptacaine or hexathricin         |
|          | or hexylcaine or instillagel or ipravacaine or isobutamben or ketocaine or levobupivacaine or lidamidine or lidocaine ormepivacaine        |
|          | ormeprylcaine ormetabutethamine ormyrtecaine or oxetacaine or oxybuprocaine or pentacaine or phenacaine or phenol or piperocaine o         |
|          | polidocanol or pramocaine or prilocaine or procaine or propanocaine or propoxycaine or propylcaine or proxymetacaine or pseudococair       |
|          | or pyrrocaine or quinisocaine or ropivacaine or tanax or tetracaine or tetrodotoxin or tolycaine or tricaine or trimecaine or xyloproct or |
|          | zolamine).tw.  |
| 8        | l or 2   |
| 9        | 3 or 4   |
| 0        | 5 or 6   |
| I        | 7 or 8   |
| 2        | 9 or 10  |
| 3        | II or I2   |
| 4        | 13 or 14   |
| 5        | 15 or 16 or 17   |
| 6        | 19 or 20 or 21 or 22 or 23 or 24 or 25   |
| 27       | 18 and 26  |
| 28       | (('clinical':ti,ab and 'trial':ti,ab) or 'clinical trial' exp or random* or 'drug therapy':lnk).af.  |
| 29       | 27 and 28  |

#### Table S2 Definitions

| Study                             | Duration of analgesia   | Duration of motor block  |
|-----------------------------------|---|--|
| Abdelmonem and Rizk <sup>1</sup>  | Duration of analgesia was measured after the onset of sensory blockade till the patient's first request of analgesia (VAS >3).                  | None   |
| Desmet et al <sup>2</sup>         | Duration of analgesia was defined as the time between the performance of the block and the first administration of analgesia.                   | None   |
| Kawanishi et al <sup>3</sup>      | Duration of analgesia was defined as the time between the performance of<br>the sensory block and the first administration of analgesia         | None   |
| Rahangdale et al⁴                 | Duration of analgesia was defined as the time to first reported pain  | Duration of motor block was defined as the time to first toe movement                                  |
| Abdallah et al⁵                   | Duration of analgesia was defined as the time in hours to the first report of postoperative pain at the surgical site.                          | Duration of motor block, defined as the time (in hours) to return to normal                            |
| Rosenfeld et al <sup>6</sup>      | Duration of analgesia was defined as the time from injection until the patient detected complete resolution of sensory blockade                 | None   |
| Chun et al <sup>7</sup>           | The definition of "median analgesia time" was the time to first analgesic request in >50% of patients.  | None   |
| Aliste et al <sup>8</sup>         | For duration of postoperative analgesia, patients were instructed to record<br>the exact time they first experienced pain at the surgical site. | Duration of motor block, defined<br>as the exact time they first regained<br>movement of their fingers |
| Dawson et al <sup>9</sup>         | Durations of blockade was defined as the time until ankle and foot sensation<br>or movement started to return.                                  | None   |
| Leurcharusmee et al <sup>10</sup> | For duration of postoperative analgesia, patients were instructed to record<br>the exact time they first experienced pain at the surgical site. | Duration of motor block, defined<br>as the exact time they first regained<br>movement of the fingers   |

Abbreviation: VAS, visual analog scale.




Figure S1 Risks of bias for the ten included studies by all authors' judgment. Notes: Red, high risk of bias; yellow, unclear risk of bias; green, low risk of bias.




Figure S2 Funnel plots of duration of analgesia: adding epinephrine (left) and not adding epinephrine (right).




Figure S3 Funnel plot of postoperative nausea and vomiting.

#### References

- Abdelmonem A, Rizk SN. Comparative study between intravenous and local dexamethasone as adjuvant to bupivacaine in perianal block. *Egypt J Anaesth.* 2011;27(3):163–168.
- Desmet M, Braems H, Reynvoet M, et al. I.V. and perineural dexamethasone are equivalent in increasing the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder surgery: a prospective, randomized, placebo-controlled study. *Br J Anaesth*. 2013;111(3):445–452.
- Kawanishi R, Yamamoto K, Tobetto Y, et al. Perineural but not systemic low-dose dexamethasone prolongs the duration of interscalene block with ropivacaine: a prospective randomized trial. *Local Reg Anesth.* 2014; 7:5–9.
- Rahangdale R, Kendall MC, McCarthy RJ, et al. The effects of perineural versus intravenous dexamethasone on sciatic nerve blockade outcomes: a randomized, double-blind, placebo-controlled study. *Anesth Analg.* 2014;118(5):1113–1119.
- Abdallah FW, Johnson J, Chan V, et al. Intravenous dexamethasone and perineural dexamethasone similarly prolong the duration of analgesia after supraclavicular brachial plexus block: a randomized, triple-arm, double-blind, placebo-controlled trial. *Reg Anesth Pain Med*. 2015;40(2):125–132.

- Rosenfeld DM, Ivancic MG, Hattrup SJ, et al. Perineural versus intravenous dexamethasone as adjuncts to local anaesthetic brachial plexus block for shoulder surgery. Anaesthesia. 2016;71(4):380–388.
- Chun EH, Kim YJ, Woo JH. Which is your choice for prolonging the analgesic duration of single-shot interscalene brachial blocks for arthroscopic shoulder surgery? Intravenous dexamethasone 5 mg vs. perineural dexamethasone 5 mg randomized, controlled, clinical trial. *Medicine (Baltimore)*. 2016;95(23):e3828.
- Aliste J, Leurcharusmee P, Engsusophon P, et al. A randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided axillary block. *Can J Anaesth.* 2017;64(1):29–36.
- Dawson RL, McLeod DH, Koerber JP, Plummer JL, Dracopoulos GC. A randomised controlled trial of perineural vs intravenous dexamethasone for foot surgery. Anaesthesia. 2016;71(3):285–290.
- Leurcharusmee P, Aliste J, Van Zundert TC, et al. A multicenter randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided infraclavicular block. Reg Anesth Pain Med. 2016;41(3):328–333.
- 11. Chun EH, Kim YJ, Woo JH. Which is your choice for prolonging the analgesic duration of single-shot interscalene brachial blocks for arthroscopic shoulder surgery? Intravenous dexamethasone 5 mg vs. perineural dexamethasone 5 mg randomized, controlled, clinical trial. *Medicine (Baltimore)*. 2016;95(23):e3828.

#### Journal of Pain Research

#### Publish your work in this journal

The Journal of Pain Research is an international, peer reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication.

Submit your manuscript here: https://www.dovepress.com/journal-of-pain-research-journal

#### **Dove**press

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.